FDA gives ap­proval to No­var­tis' man­u­fac­tur­ing site for Plu­vic­to

No­var­tis said Fri­day that the pro­duc­tion fa­cil­i­ty for its ra­di­oli­gand ther­a­py Plu­vic­to has got­ten the thumbs-up from the FDA, and it plans to be­gin sup­ply­ing the prostate can­cer treat­ment for com­mer­cial use in the US from the new fa­cil­i­ty in Mill­burn, NJ.

The Swiss phar­ma said in a re­lease that man­u­fac­tur­ing is slat­ed to start in the com­ing weeks with a grad­ual ramp-up in pro­duc­tion, and ca­pac­i­ty at the fa­cil­i­ty is al­so ex­pect­ed to in­crease through­out the sec­ond half of this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.